| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-11-19 | Merck KGaA (Germany) the University of Cape Town (UCT) (South Africa) | anti-malarial drug candidates | malaria | R&D |
Infectious diseases - Parasitic diseases | R&D agreement |
| 2015-11-19 | ProMetic Life Sciences (Canada) ProThera Biologics (USA - RI) | human plasma-derived Inter-alpha Inhibitor Proteins | development |
Rare diseases | Development agreement | |
| 2015-11-18 | Onxeo (France) Synovo (Germany) | collaboration |
Cancer - Oncology - Rare diseases | Collaboration agreement | ||
| 2015-11-18 | Onxeo (France) Croix-Rousse Hospital (France) | Livatag® (doxorubicin Transdrug™), Beleodaq® (belinostat) | collaboration |
Cancer - Oncology - Rare diseases | Collaboration agreement | |
| 2015-11-17 | Poxel (France) ENYO Pharma (France) | FXR (farnesoid X receptor) agonist compounds | hepatitis B | licensing |
Infectious diseases | Licensing agreement |
| 2015-11-17 | Biophytis (France) | Biophytis Inc | establishment of a new subsidiary in the US |
Metabolic diseases - Neurodegenerative diseases - Ophtalmological diseases | Establishment of a new subsidiary in the US | |
| 2015-11-17 | Therametrics (Switzerland) | restructuring |
Restructuring | |||
| 2015-11-17 | Cancer Research Technology (CRT) Medivir (Sweden) | ADAM8 inhibitor drugs including BK-1361 | pancreatic cancer | licensing collaboration |
Cancer - Oncology | Termination of an agreement |
| 2015-11-17 | Morphotek (USA - PA), a subsidiary of Eisai (Japan) Targeted Alpha Therapy Group (TAT Group) (Sweden) | farletuzumab | ovarian cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2015-11-16 | Baxalta (USA - IL) | Baxalta Singapore Facility | validation of a production plant |
Rare diseases - Genetic diseases - Hematological diseases | Validation of a production plant | |
| 2015-11-16 | Hybrigenics (France) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-11-16 | PharmaMar (Spain) | establishment of a new subsidiary in the EU |
Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2015-11-12 | Roche (Switzerland) | manufacturing network | restructuring |
Restructuring | ||
| 2015-11-12 | Cerulean Pharma (USA - MA) AstraZeneca (UK) National Cancer Institute (NCI) (USA) | Lynparza™ (olaparib) and CRLX101 - poly-CD-PEG-camptothecin | small cell lung cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-11-11 | SELLAS Life Sciences (Switzerland) | nomination |
Cancer - Oncology - CNS diseases | Nomination | ||
| 2015-11-11 | ProMetic Life Sciences (Canada) Omnio (Sweden) | plasminogen | hard-to-treat wounds including diabetic foot ulcers | licensing |
Licensing agreement | |
| 2015-11-10 | Imabiotech (France) Galderma (Switzerland) | Multimaging™ services | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-11-10 | Pierre Fabre (France) EPFL (Switzerland) | biosensor chips | schizophrenia | collaboration R&D |
CNS diseases - Mental diseases | R&D agreement |
| 2015-11-10 | Novasep (France) Centre for Process Innovation (CPI) (UK) | services contract |
Technology - Services | Services contract | ||
| 2015-11-10 | AmpliPhi BioSciences (USA - VA) | nomination |
Infectious diseases | Nomination |
